Diagnostic accuracy of plasma p‐tau217/Aβ42 for Alzheimer's disease in clinical and community cohorts
Alzheimer's & Dementia · 2025-03 · 21 (3)
DOI: 10.1002/alz.70038 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 29.03.2025. Verfasst von Jun Wang und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Center for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China. Hauptthemen laut MEDLINE: tau Proteins, Alzheimer Disease, Amyloid beta-Peptides, Peptide Fragments. Die Arbeit wurde bisher 116-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Chongqing Science and Technology Bureau and the Health Commission.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION This study was undertaken to evaluate the diagnostic performance of a novel plasma phosphorylated tau (p‐tau) 217/amyloid beta (Aβ) 42 ratio test for Alzheimer's disease (AD). METHODS The diagnostic performance of the Lumipulse G plasma p‐tau217/Aβ42 ratio was evaluated using Aβ and tau positron emission tomography (PET) as reference standards in a clinic cohort ( n = 391) and a community cohort ( n = 121). RESULTS Plasma p‐tau217/Aβ42 exhibited high performance for abnormal statuses of Aβ PET (area under the curve [AUC]: 0.963 to 0.966) and tau PET (AUC: 0.947 to 0.974), which were clinically equivalent to those of cerebrospinal fluid (CSF) p‐tau181/Aβ42 and Aβ42/Aβ40 and higher than those of blood p‐tau217, Aβ42/Aβ40, p‐tau181, and p‐tau181/Aβ42 in both clinic and community cohorts. Applying a two‐cutoff approach improved the specificity without reducing sensitivity. The p‐tau217/Aβ42 ratio had a lower intermediate percentage than p‐tau217 alone in both clinic (10.6% vs 13.0%) and community (16.5% vs 31.4%) cohorts. DISCUSSION Plasma p‐tau217/Aβ42 has high performance in detecting cerebral AD pathologies, thus offering a promising tool for clinical diagnosis and community screening of AD. Highlights Lumipulse G plasma p‐tau217 and the p‐tau217/Aβ42 ratio accurately identified abnormal Aβ and tau PET statuses in both clinical and community cohorts. The performance of plasma p‐tau217 and p‐tau217/Aβ42 ratio were equivalent to CSF tests. Plasma p‐tau217/Aβ42 ratio outperformed p‐tau217 alone in identifying Aβ PET positivity, and this superiority is more obvious in the community cohort, suggesting an advantage in the early diagnosis of AD. Two cut points of p‐tau217/Aβ42 were established in the Chinese population for clinical laboratory and community screening uses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology and Center for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China.
- Chongqing Key Laboratory of Ageing and Brain Diseases, Chongqing, China.
- Institute of Biomedical Engineering, Shenzhen Bay Laboratory, Shenzhen, China.
- Chongqing Institute for Brain and Intelligence, Guangyang Bay Laboratory, Chongqing, China.
- Department of Nuclear Medicine, Daping Hospital, Third Military Medical University, Chongqing, China.
- Australian eHealth Research Centre, CSIRO Health and Biosecurity, Brisbane, Queensland, Australia.
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Chongqing Science and Technology Bureau and the Health Commission
- Guangdong Basic and Applied Basic Science Foundation
- Shenzhen Bay Laboratory
- Swedish Research Council supported by grants from the Swedish Research Council
- European Union's Horizon Europe Research and Innovation Programme
- Swedish State Support for Clinical Research
Zitieren
APA
Wang, J., Huang, S., Lan, G., Lai, Y. J., Wang, Q. H., Chen, Y., Xiao, Z. S., Chen, X., Bu, X. L., Liu, Y. H., Zeng, F., Zhang, L., Li, A., Cai, Y., Sun, P., He, Z., Doré, V., Fripp, J., Bourgeat, P., …, & Translational Biomarker Research of AgIng and Neurodegeneration (TBRAIN) (2025). Diagnostic accuracy of plasma p‐tau217/Aβ42 for Alzheimer's disease in clinical and community cohorts. Alzheimer's & Dementia, 21(3). https://doi.org/10.1002/alz.70038
Vancouver
Wang J, Huang S, Lan G, Lai YJ, Wang QH, Chen Y, et al. Diagnostic accuracy of plasma p‐tau217/Aβ42 for Alzheimer's disease in clinical and community cohorts. Alzheimer's & Dementia. 2025;21(3). doi:10.1002/alz.70038
BibTeX
@article{Wang2025,
author = {Wang, Jun and Huang, Shan and Lan, Guoyu and Lai, Yu-Jie and Wang, Qing-Hua and Chen, Yang and Xiao, Zhong-Song and Chen, Xiao and Bu, Xian-Le and Liu, Yu-Hui and Zeng, Fan and Zhang, Laihong and Li, Anqi and Cai, Yue and Sun, Pan and He, Zhengbo and Doré, Vincent and Fripp, Jurgen and Bourgeat, Pierrick and Chen, Qin and Yu, Jin-Tai and Tang, Yi and Zetterberg, Henrik and Masters, Colin L and Guo, Tengfei and Wang, Yan-Jiang and Translational Biomarker Research of AgIng and Neurodegeneration (TBRAIN), Translational Biomarker Research of AgIng and Neurodegeneration (TBRAIN)},
title = {Diagnostic accuracy of plasma p‐tau217/Aβ42 for Alzheimer's disease in clinical and community cohorts},
journal = {Alzheimer's & Dementia},
year = {2025},
volume = {21},
number = {3},
doi = {10.1002/alz.70038}
}
EUVIMED